Blood test may predict chemo failure in aggressive breast cancer

NCT ID NCT04771871

First seen May 08, 2026 · Last updated May 08, 2026

Summary

This study looks at 42 women with triple negative breast cancer, an aggressive type that lacks targeted treatments. Participants receive standard chemotherapy, and researchers will measure tiny molecules in the blood (microRNA and tumor DNA) to see if changes can signal when the drugs stop working. The goal is to find a simple blood test to monitor treatment response and catch relapse early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lagos State University Teaching Hospital

    NOT_YET_RECRUITING

    Lagos, Nigeria

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Lagos University Teaching Hospital

    NOT_YET_RECRUITING

    Lagos, Nigeria

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Obafemi Awolowo University Teaching Hospital

    NOT_YET_RECRUITING

    Ile-Ife, Oshun, Nigeria

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University College Hospital

    RECRUITING

    Ibadan, Oyo State, 200221, Nigeria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.